Estimating the cost consequence of the early use of botulinum toxin in post-stroke spasticity: Secondary analysis of a randomised controlled trial
Authors: Lindsay, C., Humphreys, I., Phillips, C. and Pandyan, A.
Journal: Clinical Rehabilitation
Volume: 37
Issue: 3
Pages: 373-380
eISSN: 1477-0873
ISSN: 0269-2155
DOI: 10.1177/02692155221133522
Abstract:Objective: To estimate the cost-consequence of treating spasticity early with botulinum toxin in the acute stroke unit. Design: Secondary cost-consequence analysis, using data from a double-blind randomised-controlled trial. Setting: Single-centre specialised stroke unit. Subjects and Interventions: Patients with Action Research Arm Test grasp-score of <2 and who developed spasticity within six weeks of a first stroke were randomised to receive injections of: 0.9% sodium-chloride solution (placebo) or onabotulinumtoxin-A (treatment). Main measures: Resource use costs were calculated for the study. Mean contracture costs for each group were calculated. The Barthel Index and Action Research Arm Test were used to generate a cost per unit of improvement. Results: There were no significant differences associated with early treatment use. The mean contracture cost for the treatment group was £817 and for the control group was £2298 (mean difference = −£1481.1(95% CI −£2893.5, −£68.7) (p = 0.04). The cost per unit of improvement for the Barthel Index was −£1240 indicating that the intervention costs less and is more effective. The cost per unit of improvement for the Action Research Arm Test was −£450 indicating that the intervention costs less and is more effective. Conclusions: Treating spasticity early in stroke patients at risk of contractures with botulinum toxin leads to a significant reduction in contracture costs. The cost per improvement of Barthel and Action Research Arm Test indicates that the intervention costs less and is more effective. Trial Registration data: EudraCT(2010-021257-39) and ClinicalTrials.gov-Identifier:NCT01882556.
https://eprints.bournemouth.ac.uk/37800/
Source: Scopus
Estimating the cost consequence of the early use of botulinum toxin in post-stroke spasticity: Secondary analysis of a randomised controlled trial.
Authors: Lindsay, C., Humphreys, I., Phillips, C. and Pandyan, A.
Journal: Clin Rehabil
Volume: 37
Issue: 3
Pages: 373-380
eISSN: 1477-0873
DOI: 10.1177/02692155221133522
Abstract:OBJECTIVE: To estimate the cost-consequence of treating spasticity early with botulinum toxin in the acute stroke unit. DESIGN: Secondary cost-consequence analysis, using data from a double-blind randomised-controlled trial. SETTING: Single-centre specialised stroke unit. SUBJECTS AND INTERVENTIONS: Patients with Action Research Arm Test grasp-score of <2 and who developed spasticity within six weeks of a first stroke were randomised to receive injections of: 0.9% sodium-chloride solution (placebo) or onabotulinumtoxin-A (treatment). MAIN MEASURES: Resource use costs were calculated for the study. Mean contracture costs for each group were calculated. The Barthel Index and Action Research Arm Test were used to generate a cost per unit of improvement. RESULTS: There were no significant differences associated with early treatment use. The mean contracture cost for the treatment group was £817 and for the control group was £2298 (mean difference = -£1481.1(95% CI -£2893.5, -£68.7) (p = 0.04). The cost per unit of improvement for the Barthel Index was -£1240 indicating that the intervention costs less and is more effective. The cost per unit of improvement for the Action Research Arm Test was -£450 indicating that the intervention costs less and is more effective. CONCLUSIONS: Treating spasticity early in stroke patients at risk of contractures with botulinum toxin leads to a significant reduction in contracture costs. The cost per improvement of Barthel and Action Research Arm Test indicates that the intervention costs less and is more effective. TRIAL REGISTRATION DATA: EudraCT(2010-021257-39) and ClinicalTrials.gov-Identifier:NCT01882556.
https://eprints.bournemouth.ac.uk/37800/
Source: PubMed
Estimating the cost consequence of the early use of botulinum toxin in post-stroke spasticity: Secondary analysis of a randomised controlled trial
Authors: Lindsay, C., Humphreys, I., Phillips, C. and Pandyan, A.
Journal: CLINICAL REHABILITATION
Volume: 37
Issue: 3
Pages: 373-380
eISSN: 1477-0873
ISSN: 0269-2155
DOI: 10.1177/02692155221133522
https://eprints.bournemouth.ac.uk/37800/
Source: Web of Science (Lite)
Estimating the cost consequence of the early use of botulinum toxin in post-stroke spasticity: Secondary analysis of a randomised controlled trial.
Authors: Lindsay, C., Humphreys, I., Phillips, C. and Pandyan, A.
Journal: Clinical rehabilitation
Volume: 37
Issue: 3
Pages: 373-380
eISSN: 1477-0873
ISSN: 0269-2155
DOI: 10.1177/02692155221133522
Abstract:Objective
To estimate the cost-consequence of treating spasticity early with botulinum toxin in the acute stroke unit.Design
Secondary cost-consequence analysis, using data from a double-blind randomised-controlled trial.Setting
Single-centre specialised stroke unit.Subjects and interventions
Patients with Action Research Arm Test grasp-score of <2 and who developed spasticity within six weeks of a first stroke were randomised to receive injections of: 0.9% sodium-chloride solution (placebo) or onabotulinumtoxin-A (treatment).Main measures
Resource use costs were calculated for the study. Mean contracture costs for each group were calculated. The Barthel Index and Action Research Arm Test were used to generate a cost per unit of improvement.Results
There were no significant differences associated with early treatment use. The mean contracture cost for the treatment group was £817 and for the control group was £2298 (mean difference = -£1481.1(95% CI -£2893.5, -£68.7) (p = 0.04). The cost per unit of improvement for the Barthel Index was -£1240 indicating that the intervention costs less and is more effective. The cost per unit of improvement for the Action Research Arm Test was -£450 indicating that the intervention costs less and is more effective.Conclusions
Treating spasticity early in stroke patients at risk of contractures with botulinum toxin leads to a significant reduction in contracture costs. The cost per improvement of Barthel and Action Research Arm Test indicates that the intervention costs less and is more effective.Trial registration data
EudraCT(2010-021257-39) and ClinicalTrials.gov-Identifier:NCT01882556.https://eprints.bournemouth.ac.uk/37800/
Source: Europe PubMed Central
Estimating the cost consequence of the early use of botulinum toxin in post-stroke spasticity: Secondary analysis of a randomised controlled trial.
Authors: Lindsay, C., Humphreys, I., Phillips, C. and Pandyan, A.
Journal: Clinical Rehabilitation
Volume: 37
Issue: 3
Pages: 373-380
ISSN: 0269-2155
Abstract:OBJECTIVE: To estimate the cost-consequence of treating spasticity early with botulinum toxin in the acute stroke unit. DESIGN: Secondary cost-consequence analysis, using data from a double-blind randomised-controlled trial. SETTING: Single-centre specialised stroke unit. SUBJECTS AND INTERVENTIONS: Patients with Action Research Arm Test grasp-score of <2 and who developed spasticity within six weeks of a first stroke were randomised to receive injections of: 0.9% sodium-chloride solution (placebo) or onabotulinumtoxin-A (treatment). MAIN MEASURES: Resource use costs were calculated for the study. Mean contracture costs for each group were calculated. The Barthel Index and Action Research Arm Test were used to generate a cost per unit of improvement. RESULTS: There were no significant differences associated with early treatment use. The mean contracture cost for the treatment group was £817 and for the control group was £2298 (mean difference = -£1481.1(95% CI -£2893.5, -£68.7) (p = 0.04). The cost per unit of improvement for the Barthel Index was -£1240 indicating that the intervention costs less and is more effective. The cost per unit of improvement for the Action Research Arm Test was -£450 indicating that the intervention costs less and is more effective. CONCLUSIONS: Treating spasticity early in stroke patients at risk of contractures with botulinum toxin leads to a significant reduction in contracture costs. The cost per improvement of Barthel and Action Research Arm Test indicates that the intervention costs less and is more effective. TRIAL REGISTRATION DATA: EudraCT(2010-021257-39) and ClinicalTrials.gov-Identifier:NCT01882556.
https://eprints.bournemouth.ac.uk/37800/
Source: BURO EPrints